EquitiesIndia.com

Healthcare · Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Ltd.

ZYDUSLIFE

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

NSE: ZYDUSLIFEOfficial website ↗

Key metrics

Market Cap

₹92,111 cr

P/E Ratio

18.65x

P/B Ratio

3.85x

ROE

18.89%

ROCE

22.53%

Debt / Equity

0.13x

Net Margin

20.05%

Dividend Yield

120%

EPS

₹44.97

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 75.17%FII: 13.74%Public: 11.09%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Zydus Lifesciences Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.